Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $12.1 million.

  • UroGen Pharma's Prepaid Assets fell 1374.08% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 1374.08%. This contributed to the annual value of $8.8 million for FY2024, which is 1396.75% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Prepaid Assets is $12.1 million, which was down 1374.08% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Prepaid Assets ranged from a high of $16.0 million in Q3 2023 and a low of $5.3 million during Q2 2021
  • For the 5-year period, UroGen Pharma's Prepaid Assets averaged around $10.6 million, with its median value being $10.6 million (2022).
  • In the last 5 years, UroGen Pharma's Prepaid Assets surged by 30695.88% in 2021 and then crashed by 1396.75% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Prepaid Assets stood at $7.5 million in 2021, then skyrocketed by 48.49% to $11.1 million in 2022, then fell by 7.39% to $10.3 million in 2023, then fell by 13.97% to $8.8 million in 2024, then soared by 37.05% to $12.1 million in 2025.
  • Its Prepaid Assets stands at $12.1 million for Q3 2025, versus $12.1 million for Q2 2025 and $13.0 million for Q1 2025.